GLP-1 and alcohol: none of the four main labels (Ozempic, Wegovy, Mounjaro, Zepbound) lists alcohol as a drug interaction or bans it.[5][6][7][8] The real cautions are indirect: low blood sugar if you also take insulin or a sulfonylurea, more nausea and dehydration, and pancreatitis, for which heavy drinking is a common cause. Separately, a 48-person trial found that low-dose semaglutide cut alcohol craving and drinks per drinking day.[1]
This guide covers semaglutide (see our semaglutide profile), tirzepatide (see the tirzepatide profile) and other drugs in the class. For an overview of how these medicines work, start at the GLP-1 basics hub.
What the drug labels say about alcohol
The prescribing information for each brand has no alcohol-specific warning. Alcohol does not appear in the drug interaction sections either.[5][6][7][8] That does not mean drinking carries no extra risk on these drugs. Several label warnings overlap with known effects of alcohol:
| Label warning | How alcohol can add to it |
|---|---|
| Low blood sugar with insulin or sulfonylureas[5][7] | Alcohol without food can lower blood sugar and mask early symptoms[10] |
| Acute pancreatitis[6][8] | Heavy alcohol use is among the most common causes of pancreatitis[9] |
| Nausea, vomiting and diarrhea; kidney injury from dehydration[5] | Alcohol can upset the stomach and add to fluid loss |
Your prescriber knows your other medicines and health history, so ask them what amount of alcohol, if any, makes sense for you.
Low blood sugar: who is at risk
On their own, GLP-1 drugs release insulin only when blood sugar is raised, so low blood sugar (hypoglycemia) is uncommon. The risk changes when they are combined with other diabetes drugs. The Ozempic and Mounjaro labels warn that people also using an insulin secretagogue, such as a sulfonylurea, or insulin may have a higher risk of hypoglycemia, including severe hypoglycemia, and that the dose of those drugs may need to be lowered.[5][7] The Wegovy label carries the same warning.[6]
Alcohol adds a second layer. NIDDK lists drinking too much alcohol without enough food as a cause of low blood glucose, and notes that alcohol can hide the first warning signs, which can lead to severe symptoms. Its advice is to eat when you drink.[10]
Pancreatitis and alcohol
All four labels warn that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been seen in people taking GLP-1 receptor agonists. They tell patients to watch for persistent, severe stomach pain that may spread to the back, with or without vomiting, and to stop the drug if pancreatitis is suspected.[5][6][7][8]
Heavy alcohol use is, independently, one of the most common causes of pancreatitis, and a leading cause of the chronic form.[9] No trial has measured whether drinking and GLP-1 treatment together raise pancreatitis risk more than either alone. Because both are linked to the condition, heavy or binge drinking is worth discussing with your prescriber before starting.
Nausea, vomiting and dehydration
Stomach side effects are the most common problems on these drugs. They are usually worst in the weeks after starting or raising the dose. The labels also warn about acute kidney injury, mostly in people who became dehydrated from nausea, vomiting or diarrhea.[5] Alcohol can irritate the stomach and add to fluid loss, so a night of drinking during a dose increase may make side effects worse. Our GLP-1 nausea guide covers ways to manage stomach symptoms.
Many people also eat much smaller meals on a GLP-1 drug. Drinking on a near-empty stomach is linked to low blood sugar,[10] so pairing alcohol with food is a sensible habit. For what to eat, see our GLP-1 diet guide.
Do GLP-1 drugs reduce drinking?
Animal studies and health-record studies have suggested that GLP-1 drugs may reduce alcohol intake, and researchers are now testing this in randomized trials.[1]
| Study | Design | Main finding |
|---|---|---|
| Semaglutide, Hendershot et al. 2025 | 9-week RCT, 48 adults with alcohol use disorder | Less alcohol drunk in a lab test, fewer drinks per drinking day, less craving; no change in drinking days[1] |
| Exenatide, Klausen et al. 2022 | 26-week RCT, 127 patients | No reduction in heavy drinking days overall; reductions in a subgroup with BMI over 30[2] |
| Semaglutide, Wang et al. 2024 | Health-record cohort, 83,825 people with obesity | 50% to 56% lower risk of new or recurrent alcohol use disorder diagnoses vs other weight-loss drugs[3] |
| Semaglutide and liraglutide, Lähteenvuo et al. 2025 | Swedish national cohort, 227,866 people with alcohol use disorder | Lower risk of alcohol-related hospitalization during use (adjusted HR 0.64 semaglutide, 0.72 liraglutide)[4] |
The semaglutide trial
In the Hendershot trial, adults with alcohol use disorder who were not seeking treatment took semaglutide at low doses (0.25 mg, then 0.5 mg, then one week at 1.0 mg) or placebo.[1] Semaglutide reduced how much alcohol people drank during a lab self-administration session. It also lowered drinks per drinking day and weekly craving. It did not change average drinks per day or the number of drinking days.[1]
The exenatide trial
The exenatide trial was larger and longer, but it missed its main goal: heavy drinking days did not fall significantly overall. Brain scans showed lower reactivity to alcohol cues, and an exploratory analysis found less drinking in people with obesity.[2]
Observational studies
Two large cohorts link semaglutide and liraglutide to fewer alcohol use disorder diagnoses and hospital admissions.[3][4] Both are observational, so they can find associations but cannot prove cause and effect. People who start these drugs can differ in many ways from people who do not.
Practical tips if you choose to drink
- Ask first. Check with your prescriber, especially if you take insulin or a sulfonylurea or have had pancreatitis.
- Start with less. You may be eating much less than before, so try less than your usual amount and see how you feel.
- Eat and hydrate. Have food with alcohol and drink water between drinks.[10]
- Avoid dose-change weeks. Side effects tend to peak after a dose increase.
- Know the warning signs. Severe stomach pain that spreads to the back needs prompt medical care.[6]
If you are planning to stop treatment, read what happens when you stop a GLP-1. If weight loss has stalled, see not losing weight on a GLP-1.
